Skip to main content
. 2024 Dec 12;16(12):1589. doi: 10.3390/pharmaceutics16121589

Figure 3.

Figure 3

Deposition of TRES using TRES-NLC formulation F14 in various stages (1–8) of NGI via air-jet and ultrasonic nebulizers. Data are mean ± SD, n = 3.